334 Results Found for “cardiac device”
Immediate 14-day ambulatory ECG monitoring did not significantly reduce recurrent syncope at 1 year in the ASPIRED trial, but it more than doubled the detection of clinically significant arrhythmias and enabled earlier diagnosis and treatment. Following the presentation, Prof. Matthew Reed, from the Usher Institute, University of Edinburgh, and the Emergency Medicine Research Group Edinburgh, spoke about the origins of ASPIRED, the importance of earlier investigation for patients with syncope, and how this approach might be incorporated into routine care.
Cardiovascular diseases (CVDs) are the leading cause of morbidity and mortality worldwide.1 High systolic blood pressure (SBP) remains one of the top risk factors for CVD burden globally.2 Despite being a modifiable risk factor, hypertension (HTN) remains largely undiagnosed and ...
New 2026 ESC Guidelines for the management of heart failure introduce major changes to the classification of heart failure and its treatment, with an increased focus on prevention, earlier intervention and timely referral of patients with advanced disease.
Late-breaking clinical research will once again be a major focus at ESC Congress 2026, taking place in Munich, Germany, from August 28–31. This year, a record 59 trials have been selected for presentation across 12 Hot Line sessions, spanning new pharmacological approaches, diagnostic strategies, devices, imaging and digital technologies.
At EHRA 2026, Professor Claudio Tondo presents his highlights on advances in ablation and device technologies, led by pulsed field ablation, showcasing a rapidly evolving landscape in the treatment of complex arrhythmias.
Ventricular fibrillation (VF) is characterized by rapid (>300 beats a per minute), irregular electrical activation with variable electrocardiographic waveforms that prevents coordinated myocardial contraction, resulting in immediate loss of cardiac output.1 It most commonly occurs in the context of coronary ...
Cardiovascular care continues to evolve in response to increasingly complex clinical realities, where advances in intervention, electrophysiology and population health must be integrated with a more critical appraisal of long-held assumptions. Across disciplines, there is a growing recognition that improving ...
Sudden cardiac arrest (SCA) in young adults (typically defined as individuals younger than 40 years) has emerged as an important yet under-recognized public health concern. Recent estimates suggest an incidence of approximately 1–4 cases per 100,000 person-years, underscoring the clinical and epidemiological relevance ...
After decades of debate, patent foramen ovale (PFO) closure is now a well-established strategy to reduce recurrent stroke in patients aged 18–60 years who have had a PFO-associated stroke.1 Patients who underwent PFO closure continue to have a higher stroke risk ...
Data presented on the first day of EuroPCR 2026, Paris, highlighted continued advances in lipid lowering, coronary scaffold technology and vessel restoration strategies. From substantial reductions in cardiovascular events with aggressive LDL-cholesterol lowering to encouraging long-term outcomes with next-generation bioresorbable and adaptive coronary devices, these studies offered important insights into the future direction of PCI and secondary prevention.
The ASPC launches a new working group to guide the safe, evidence-based integration of AI and digital health technologies into preventive cardiology practice - we spoke to co-Chair Dr Ashish Sarraju about the state of artificial intelligence and health technology and the group's concerns plans for the future.
Hypertension affects over 1.4 billion adults worldwide and remains the leading modifiable risk factor for global cardiovascular (CV) morbidity and mortality. It is responsible for an estimated 10.8 million deaths annually and contributes significantly to the global burden of ischaemic heart disease, ...
Atrial fibrillation (AF) remains a major clinical challenge in Europe, with ongoing needs for greater precision, safety, and long-term durability in ablation. The recent CE Mark approval of the TactiFlex™ Duo Ablation Catheter, combining high-resolution mapping with emerging pulsed-field ablation (PFA) technology, offers a new option to help address these gaps. Dr John Silberbauer explores how the device may enhance AF treatment, reviews the supporting clinical evidence, and considers what this milestone means for physicians and patients across Europe.
Adult congenital heart disease is no longer a niche condition confined to childhood, but a lifelong and increasingly complex cardiovascular diagnosis. The new ACC/AHA guideline reframes care around continuity with specialised services, proactive mental health assessment, and encouragement of safe physical activity, signalling a shift from lesion-focused surveillance to holistic, life-course management that better reflects the realities facing today’s adult patients.
Keep track of your clinical interests and newsletter subscriptions.
Register for free to hear about the latest expert-led education, peer-reviewed articles, conference highlights, and innovative CME activities.
Or use a Social Account.
Already registered? Login below.